Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geron, a biopharmaceutical company, has received new US patent that covers cardiomyocytes derived from human embryonic stem cells.
Subscribe to our email newsletter
The patent runs until at least April 2025 (subject to any patent term extension that may be available). Geron’s GRNCM1 program is developing human embryonic stem cell (hESC)-derived cardiomyocytes for the treatment of heart disease.
David Earp, senior vice president of business development and chief patent counsel at Geron, said: “This patent provides broad coverage of hESC-derived cardiomyocytes for cell therapy and drug screening applications.
“The addition of this patent to our portfolio of Geron-owned and exclusively licensed intellectual property covering embryonic stem cells, technologies for scalable production of pluripotent stem cells, and methods for their differentiation will further strengthen and extend our proprietary position.”